Evidence map›Paper›PMID 40980579›Full record

ArticleOpen forum infectious diseases2025

Strategies to Minimize Time From HIV Acquisition to ART Initiation: The Barcelona Early-cART Program.

Lucia Bailón, Yovaninna Alarcón-Soto, Angel Rivero, Pep Coll, Jorge Saz, Michael Meulbroek, Irene Gonzalez-Navarro, Maria Salgado, Victor Urrea, Patricia Cobarsi and 6 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lucia BailónFundació Lluita Contra les Infeccions, Department of Infectious Diseases, Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain.ORCID https://orcid.org/0000-0001-7277-9314
Yovaninna Alarcón-SotoFundació Lluita Contra les Infeccions, Department of Infectious Diseases, Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain.ORCID https://orcid.org/0000-0002-9977-8634
Angel RiveroFundació Lluita Contra les Infeccions, Department of Infectious Diseases, Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain.ORCID https://orcid.org/0000-0003-2136-0702
Pep CollProjecte Dels NOMS-Hispanosida, BCN Checkpoint, Barcelona, Barcelona, Spain.
Jorge SazProjecte Dels NOMS-Hispanosida, BCN Checkpoint, Barcelona, Barcelona, Spain.
Michael MeulbroekProjecte Dels NOMS-Hispanosida, BCN Checkpoint, Barcelona, Barcelona, Spain.
Irene Gonzalez-NavarroIrsiCaixa, Badalona, Barcelona, Spain.ORCID https://orcid.org/0000-0002-4567-766X
Maria SalgadoIrsiCaixa, Badalona, Barcelona, Spain.
Victor UrreaIrsiCaixa, Badalona, Barcelona, Spain.ORCID https://orcid.org/0000-0002-2577-856X
Patricia CobarsiFundació Lluita Contra les Infeccions, Department of Infectious Diseases, Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain.
Eugenia NegredoFundació Lluita Contra les Infeccions, Department of Infectious Diseases, Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain.
Roger ParedesFundació Lluita Contra les Infeccions, Department of Infectious Diseases, Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain.
Javier Martinez-PicadoIrsiCaixa, Badalona, Barcelona, Spain.ORCID https://orcid.org/0000-0002-4916-2129
Christian BranderIrsiCaixa, Badalona, Barcelona, Spain.
José MoltóFundació Lluita Contra les Infeccions, Department of Infectious Diseases, Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain.ORCID https://orcid.org/0000-0003-4564-1963
Beatriz MotheFundació Lluita Contra les Infeccions, Department of Infectious Diseases, Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain.ORCID https://orcid.org/0000-0001-9975-407X

Funding

Reversing Immune Dysfunction for HIV-1 EradicationUM1AI164561 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SUMIT K CHANDA, Paula M Cannon · 2021 to 2026
$30.0M
Supplement to A Multi-omics Approach to Immune Responses in HIV Vaccination and InterventionP01AI178375 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DENNIS J. HARTIGAN-O'CONNOR, Rachel Lena Rutishauser · 2023 to 2026
$8.5M
MultiOMICS to uncover immune and virological mechanisms that drive HIV DNA decay, restore immune homeostasis, and promote HIV specific immunity in PWH receiving cell therapies.P01AI178376 · NIAID · EMORY UNIVERSITY · PI Javier Martinez-Picado · 2023 to 2026
$6.1M
NIAID NIH HHS P01 AI178375NIAID NIH HHS P01 AI178376NIAID NIH HHS UM1 AI164561
6 · The paper itself

Abstract

Background: Targeted referral systems for individuals at highest risk of HIV transmission can accelerate linkage to care and antiretroviral treatment (ART) initiation, potentially reducing onward transmission. Methods: In 2014, we established the Early-cART cohort of adults newly diagnosed with HIV who started ART within 6 months of estimated HIV acquisition (etPWH), in collaboration with community centers and via a fast-referral system to our HIV unit. Clinical data and biological samples were collected before and after initiation of ART. Total HIV-1 DNA in peripheral blood mononuclear cells was measured in a subset of participants virologically suppressed for >3 years. Link-to-care was defined as days from first positive HIV test to first appointment at the HIV unit. HIV-to-ART was defined as days from estimated acquisition to ART start. Results: From 2014 to 2022, 340 etPWH (90% men having sex with men, mean age 34 years) were included from ∼900 new referrals. Two years after ART initiation, 48% of etPWH achieved a CD4/CD8 ratio of >1, whereas only 5% remained <0.5. In the reservoir subset, levels of HIV-1 DNA correlated with time from HIV to ART only when ART was initiated within 60 days after HIV acquisition, with 55% of participants showing <50 HIV-1 DNA copies/10 Conclusions: The Early-cART program achieved rapid linkage to care and ART initiation with robust immunovirological responses, indicating its potential to reduce HIV transmission.

Indexed as

acute/recent infectionHIV reservoirrapid ART starttest-and-treat

Identifiers

PMID40980579
PMCPMC12449736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.